Epithelioid Hemangioendothelioma(EHE), Mesothelioma, Solid Tumor
Conditions
Brief summary
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
Interventions
DRUGBGC515
Capsules for oral administration
Sponsors
BridGene Biosciences Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Sequential Assignment
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Having signed the written Informed Consent Form * Male or female aged ≥18 years * Life expectancy ≥12 weeks * Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1 * Dose escalation phase: Histologically or cytologically confirmed locally advanced or metastatic mesothelioma (MM), epithelioid hemangioendothelioma (EHE), or other advanced solid tumors who have experienced progressive disease or treatment intolerability after receiving the standard-of-care, or refuse to receive or have no access to the standard-of-care * Dose expansion phase: Histologically or cytologically confirmed locally advanced or metastatic MM, EHE, etc. regardless of Hippo signaling pathway abnormalities, or other advanced solid tumors with Hippo signaling pathway abnormalities, who have experienced progressive disease or treatment intolerability after receiving the standard-of-care, or refuse to receive or have no access to the standard-of-care * At least one measurable lesion
Exclusion criteria
* Previous or current use of transcriptional enhanced associate domain (TEAD) inhibitors * Inadequate wash-out of prior therapies described per protocol * Patients with severe or unstable systemic disease, unstable or symptomatic Central Nervous System (CNS) metastasis * Clinically significant cardiovascular disease as defined in the protocol * Women who are pregnant or breastfeeding * Hypersensitivity to the active pharmaceutical ingredient or any excipient of BGC515 * Study staff member or relative of a study staff member directly related to this clinical trial, or a subordinate of the Investigator in this trial or an employee of the Sponsor, though not directly related to this trial * Serious systemic diseases or laboratory abnormalities or other conditions that, at the Investigator's discretion, will make it unsuitable for the patient to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progress-free survival(PFS) | Through study completion, approximately 3 years. | Defined as the time interval between the first dose of the treatment and the first documented disease progression or death due to any cause (whichever occurs first). Evaluated by the Investigator based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) or Response Evaluation Criteria in Solid Tumors (RECIST) V1.1. |
| Incidence of adverse events (AEs) and serious adverse events (SAEs). | Through study completion, approximately 1 year. | AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. AE evaluation will be based on laboratory tests, vital signs, physical examination, and 12-lead electrocardiogram, etc. |
| Dose-limiting toxicities (DLTs) | Within 24 days after the first dose of study drug. | DLT refers to the pre-specified AEs that occurred within 24 days after the first dose of study drug. |
| Objective response rate (ORR) | Through study completion, approximately 3 years. | Defined as the percentage of participants having complete response (CR) or partial response (PR). Evaluated by the Investigator based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) or Response Evaluation Criteria in Solid Tumors (RECIST) V1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Peak concentration (Cmax). | Multiple time points, up to approximately 1 year. | Cmax of BGC515 in plasma. |
| Time to peak concentration (Tmax). | Multiple time points, up to approximately 1 year. | Tmax of BGC515 in plasma. |
| Half-life (t1/2). | Multiple time points, up to approximately 1 year. | t1/2 of BGC515 in plasma. |
| Area under the concentration-time curve from time zero to the last detectable plasma concentration (AUC0-t). | Multiple time points, up to approximately 1 year. | (AUC0-t) of BGC515 in plasma. |
Countries
United States
Contacts
Primary ContactBridGene Biosciences
Outcome results
None listed